Kate Shearer1, Mhairi Maskew2, Toyin Ajayi3, Rebecca Berhanu4, Pappie Majuba4, Ian Sanne5, Matthew P Fox6. 1. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa. Electronic address: kshearer@heroza.org. 2. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa. 3. Center for Global Health and Development, Boston University, Boston, Massachusetts, USA. 4. Right to Care, Johannesburg, South Africa. 5. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa; Right to Care, Johannesburg, South Africa; Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 6. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa; Center for Global Health and Development, Boston University, Boston, Massachusetts, USA; Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, USA.
Abstract
OBJECTIVES: To describe the characteristics of HIV-infected patients experiencing herpes zoster after antiretroviral therapy (ART) initiation and to describe the incidence and predictors of a herpes zoster diagnosis. METHODS: Adult patients initiating ART from April 2004 to September 2011 at the Themba Lethu Clinic in Johannesburg, South Africa were included. Patients were followed from ART initiation until the date of first herpes zoster diagnosis, or death, transfer, loss to follow-up, or dataset closure. Herpes zoster is described using incidence rates (IR) and predictors of herpes zoster are presented as subdistribution hazard ratios (sHR) and 95% confidence intervals (95% CI). RESULTS: Fifteen thousand and twenty-five patients were included; 62% were female, the median age was 36.6 years, and the median baseline CD4 count was 98 cells/mm(3). Three hundred and forty patients (2.3%) experienced herpes zoster in a median of 26.1 weeks after ART initiation. Most (71.5%) occurred within 1 year of initiation, for a 1-year IR of 18.1/1000 person-years. In an adjusted model, patients with low CD4 counts (<50 vs. ≥200 cells/mm(3); sHR: 1.71, 95% CI: 1.21-2.47) and with a prior episode of herpes zoster (sHR: 1.53, 95% CI: 0.97-2.28) were at increased risk of incident herpes zoster. CONCLUSIONS: While only 2% of patients were diagnosed with herpes zoster in this cohort, patients with low CD4 counts and those with prior episodes of herpes zoster were at higher risk for a herpes zoster diagnosis.
OBJECTIVES: To describe the characteristics of HIV-infectedpatients experiencing herpes zoster after antiretroviral therapy (ART) initiation and to describe the incidence and predictors of a herpes zoster diagnosis. METHODS: Adult patients initiating ART from April 2004 to September 2011 at the Themba Lethu Clinic in Johannesburg, South Africa were included. Patients were followed from ART initiation until the date of first herpes zoster diagnosis, or death, transfer, loss to follow-up, or dataset closure. Herpes zoster is described using incidence rates (IR) and predictors of herpes zoster are presented as subdistribution hazard ratios (sHR) and 95% confidence intervals (95% CI). RESULTS: Fifteen thousand and twenty-five patients were included; 62% were female, the median age was 36.6 years, and the median baseline CD4 count was 98 cells/mm(3). Three hundred and forty patients (2.3%) experienced herpes zoster in a median of 26.1 weeks after ART initiation. Most (71.5%) occurred within 1 year of initiation, for a 1-year IR of 18.1/1000 person-years. In an adjusted model, patients with low CD4 counts (<50 vs. ≥200 cells/mm(3); sHR: 1.71, 95% CI: 1.21-2.47) and with a prior episode of herpes zoster (sHR: 1.53, 95% CI: 0.97-2.28) were at increased risk of incident herpes zoster. CONCLUSIONS: While only 2% of patients were diagnosed with herpes zoster in this cohort, patients with low CD4 counts and those with prior episodes of herpes zoster were at higher risk for a herpes zoster diagnosis.
Authors: Robert H Dworkin; Robert W Johnson; Judith Breuer; John W Gnann; Myron J Levin; Miroslav Backonja; Robert F Betts; Anne A Gershon; Maija L Haanpaa; Michael W McKendrick; Turo J Nurmikko; Anne Louise Oaklander; Michael N Oxman; Deborah Pavan-Langston; Karin L Petersen; Michael C Rowbotham; Kenneth E Schmader; Brett R Stacey; Stephen K Tyring; Albert J M van Wijck; Mark S Wallace; Sawko W Wassilew; Richard J Whitley Journal: Clin Infect Dis Date: 2007-01-01 Impact factor: 9.079
Authors: Joon Young Song; Jin Soo Lee; Hye Won Jung; Hee Jung Choi; Jin Seo Lee; Joong Shik Eom; Hee Jin Cheong; Moon Hyun Jung; Woo Joo Kim Journal: J Acquir Immune Defic Syndr Date: 2010-03 Impact factor: 3.731
Authors: Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne Journal: Int J Epidemiol Date: 2012-03-20 Impact factor: 7.196
Authors: Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke Journal: Ther Adv Vaccines Date: 2015-07
Authors: Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi Journal: Am J Trop Med Hyg Date: 2018-01-04 Impact factor: 2.345
Authors: Ruanne V Barnabas; Jared M Baeten; Jairam R Lingappa; Katherine K Thomas; James P Hughes; Nelly R Mugo; Sinead Delany-Moretlwe; Glenda Gray; Helen Rees; Andrew Mujugira; Allan Ronald; Wendy Stevens; Saidi Kapiga; Anna Wald; Connie Celum Journal: J Infect Dis Date: 2015-06-08 Impact factor: 5.226
Authors: Denise Evans; Sara Dahlberg; Rebecca Berhanu; Tembeka Sineke; Caroline Govathson; Ingrid Jonker; Elisabet Lönnermark; Matthew P Fox Journal: AIDS Care Date: 2018-02-21
Authors: Kamban Hirasen; Denise Evans; Mhairi Maskew; Ian M Sanne; Kate Shearer; Caroline Govathson; Given Malete; Sheryl A Kluberg; Matthew P Fox Journal: Clin Epidemiol Date: 2017-12-18 Impact factor: 4.790
Authors: Nathaniel B Erdmann; Heather A Prentice; Anju Bansal; Howard W Wiener; Greer Burkholder; Sadeep Shrestha; Jianming Tang Journal: Front Public Health Date: 2018-03-12
Authors: Denise Evans; Kamban Hirasen; Rebecca Berhanu; Given Malete; Prudence Ive; David Spencer; Sharlaa Badal-Faesen; Ian M Sanne; Matthew P Fox Journal: AIDS Res Ther Date: 2018-04-10 Impact factor: 2.250